Sensei Biotherapeutics to Present Topline Clinical Data From the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeut
GlobeNewswireApr 24 16:05 ET
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to
BenzingaApr 22 16:31 ET
Sensei Biotherapeutics Extends Relationship With Former CFO
TipRanksApr 12 16:43 ET
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today
GlobeNewswireApr 9 07:30 ET
Express News | Sensei Biotherapeutics Shares Are Trading Higher After the Company Announced the Publication of a Peer-reviewed Research Paper in Nature Communications the Described the Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA Within
Moomoo 24/7Apr 4 16:14 ET
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA Within the Tumor Microenvironment
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced the publication of a peer-reviewed research paper in Nature Communications.
GlobeNewswireApr 4 16:05 ET
Sensei Biotherapeutics CFO Erin Colgan Resigns Amicably
TipRanksApr 2 08:02 ET
Express News | Sensei Biotherapeutics CFO To Resign All Positions With Co Effective April 10
Moomoo 24/7Apr 2 07:48 ET
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE)
TipRanksMar 25 21:20 ET
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer
GlobeNewswireMar 22 07:30 ET
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer
GlobeNewswireMar 6 07:30 ET
Sensei Biotherapeutics (SNSE) Gets a Buy From Oppenheimer
TipRanksFeb 29 08:07 ET
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE), Abbott Labs (ABT) and Personalis (PSNL)
TipRanksFeb 29 06:50 ET
Buy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical Trials
TipRanksFeb 29 06:30 ET
Sensei Biotherapeutics Reports FY Results
Seeking AlphaFeb 28 14:19 ET
Sensei Biotherapeutics FY EPS $(1.22) Up From $(1.58) YoY; 2023 Year End Cash, Cash Equivalents And Marketable Securities Of $65.8M Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025
Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(1.22) per share. This is a 22.78 percent increase over losses of $(1.58) per share from the same period last year.
BenzingaFeb 28 07:36 ET
Sensei Biotherapeutics: Runway To Fund Operation Into 4Q 2025 >SNSE
Sensei Biotherapeutics: Runway To Fund Operation Into 4Q 2025 >SNSE
Dow JonesFeb 28 07:31 ET
Sensei Biotherapeutics Streamlines Board, Appoints Interim Chair
TipRanksFeb 9 04:56 ET
Sensei Biotherapeutics to Present at Upcoming Conferences
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer
GlobeNewswireFeb 7 07:30 ET
Buy Rating Affirmed for Sensei Biotherapeutics Amidst Promising SNS-101 Clinical Progress and Favorable Safety Data
TipRanksJan 5 06:28 ET
No Data
No Data